

RESEARCH ARTICLE

# ABCG1 and ABCG4 Suppress $\gamma$ -Secretase Activity and Amyloid $\beta$ Production

Osamu Sano<sup>1</sup>, Maki Tsujita<sup>2</sup>, Yuji Shimizu<sup>1</sup>, Reiko Kato<sup>1</sup>, Aya Kobayashi<sup>1</sup>, Noriyuki Kioka<sup>1</sup>, Alan T. Remaley<sup>3</sup>, Makoto Michikawa<sup>2</sup>, Kazumitsu Ueda<sup>1,4</sup>, Michinori Matsuo<sup>4,5\*</sup>

**1** Laboratory of Cellular Biochemistry, Division of Applied Life Sciences, Kyoto University Graduate School of Agriculture, Kyoto, 606–8502, Japan, **2** Biochemistry, Graduate School of Medical Sciences, Nagoya City University, Nagoya, 467–8601, Japan, **3** Lipoprotein Metabolism Section, NHLBI, National Institutes of Health, Bethesda, MD, 20892–1508, United States of America, **4** iCeMS, Kyoto University, Kyoto, 606–8502, Japan, **5** Department of Food and Nutrition, Faculty of Home Economics, Kyoto Women's University, Kyoto, 605–8501, Japan

\* [matsuomi@kyoto-wu.ac.jp](mailto:matsuomi@kyoto-wu.ac.jp)



**OPEN ACCESS**

**Citation:** Sano O, Tsujita M, Shimizu Y, Kato R, Kobayashi A, Kioka N, et al. (2016) ABCG1 and ABCG4 Suppress  $\gamma$ -Secretase Activity and Amyloid  $\beta$  Production. PLoS ONE 11(5): e0155400. doi:10.1371/journal.pone.0155400

**Editor:** Dong-Gyu Jo, Sungkyunkwan University, REPUBLIC OF KOREA

**Received:** April 28, 2015

**Accepted:** April 28, 2016

**Published:** May 19, 2016

**Copyright:** This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the [Creative Commons CC0](https://creativecommons.org/licenses/by/4.0/) public domain dedication.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** This work was supported by a Grant-in-aid for Scientific Research for Young Scientists (A) (JSPS KAKENHI Grant Number 21688007), by a Grant-in-aid for Scientific Research (S) (JSPS KAKENHI Grant Number 25221203), by a Grant-in-aid for Scientific Research (C) (JSPS KAKENHI Grant Number 24580139), by a Grant-in-aid for Exploratory Research (JSPS KAKENHI Grant Number 26660071), by a Grant-in-aid for Scientific Research on Priority Areas (MEXT (Ministry of Education, Culture, Sports, Science and Technology)

## Abstract

ATP-binding cassette G1 (ABCG1) and ABCG4, expressed in neurons and glia in the central nervous system, mediate cholesterol efflux to lipid acceptors. The relationship between cholesterol level in the central nervous system and Alzheimer's disease has been reported. In this study, we examined the effects of ABCG1 and ABCG4 on amyloid precursor protein (APP) processing, the product of which, amyloid  $\beta$  (A $\beta$ ), is involved in the pathogenesis of Alzheimer's disease. Expression of ABCG1 or ABCG4 in human embryonic kidney 293 cells that stably expressed Swedish-type mutant APP increased cellular and cell surface APP levels. Products of cleavage from APP by  $\alpha$ -secretase and by  $\beta$ -secretase also increased. The levels of secreted A $\beta$ , however, decreased in the presence of ABCG1 and ABCG4, but not ABCG4-KM, a nonfunctional Walker-A lysine mutant. In contrast, secreted A $\beta$  levels increased in differentiated SH-SY5Y neuron-like cells in which ABCG1 and ABCG4 were suppressed. Furthermore, A $\beta$ 42 peptide in the cerebrospinal fluid from Abcg1 null mice significantly increased compared to the wild type mice. To examine the underlying mechanism, we analyzed the activity and distribution of  $\gamma$ -secretase. ABCG1 and ABCG4 suppressed  $\gamma$ -secretase activity and disturbed  $\gamma$ -secretase localization in the raft domains where  $\gamma$ -secretase functions. These results suggest that ABCG1 and ABCG4 alter the distribution of  $\gamma$ -secretase on the plasma membrane, leading to the decreased  $\gamma$ -secretase activity and suppressed A $\beta$  secretion. ABCG1 and ABCG4 may inhibit the development of Alzheimer's disease and can be targets for the treatment of Alzheimer's disease.

## Introduction

Alzheimer's disease is characterized by extracellular senile plaques in brain tissues [1]. Amyloid  $\beta$  (A $\beta$ ), a major component of the senile plaques, plays a crucial role in the pathogenesis of Alzheimer's disease. This peptide can be 40 (A $\beta$ 40) or 42 (A $\beta$ 42) amino acids in length, after cleavage of amyloid precursor protein (APP). The precursor is cleaved by  $\alpha$ -secretase to produce

KAKENHI Grant Number 20056016), and by the World Premier International Research Center Initiative (WPI initiative) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and grants from BRAIN (the Bio-oriented Technology Research Advancement Institution).

**Competing Interests:** The authors have declared that no competing interests exist.

**Abbreviations:** ABC, ATP-binding cassette; A $\beta$ , amyloid beta; apo, apolipoprotein; APP, amyloid precursor protein; BSA, bovine serum albumin; CNS, central nervous system; CSF, cerebrospinal fluid; CTF, carboxy-terminal fragment; DMEM, Dulbecco's modified Eagle's medium; HEK, human embryonic kidney; HDL, high-density lipoprotein; LpE, apoE-containing lipoprotein; LXR, liver X receptor; M $\beta$ CD, methyl- $\beta$ -cyclodextrin; RXR, retinoid X receptor; sAPP, secreted APP.

secreted APP $\alpha$  (sAPP $\alpha$ ) and carboxy-terminal fragment  $\alpha$  (CTF $\alpha$ ) or  $\beta$ -secretase to produce sAPP $\beta$  and CTF $\beta$ , which is further cleaved by  $\gamma$ -secretase to produce A $\beta$  and CTF $\gamma$ .

Although the brain represents 3% of the average body mass, it contains 25% of the cholesterol in the body. Cholesterol levels in the brain are regulated independently of peripheral systems because cholesterol cannot cross the blood–brain barrier [2]. Cholesterol in the central nervous system (CNS) is supplied by synthesis, and excess cholesterol is converted to 24-hydroxycholesterol by CYP46A1. High levels of cholesterol are found in myelin (oligodendrocytes) in the CNS, although neurons and other glial cells also contain cholesterol. Cholesterol and apolipoprotein E (apoE) are synthesized in astrocytes, leading to the formation of apoE-containing lipoprotein (LpE), a high-density lipoprotein (HDL)-like particle that is provided to neurons and used as a component of cellular membranes or to support synaptogenesis [3] and axonal extension [4]. The correlation between cholesterol level in the brain and Alzheimer's disease has been reported. The addition of statin or methyl- $\beta$ -cyclodextrin (M $\beta$ CD) reduces the A $\beta$  formation in rat hippocampal neurons [5]. The administration of statin reduces A $\beta$  levels in rat neurons and guinea pigs [6], whereas hypercholesterolemia accelerates A $\beta$  accumulation in Alzheimer's disease model mice [7, 8]. Cholesterol is accumulated in senile plaques from Alzheimer's disease patients and Alzheimer's disease model mice [9]. There are three major alleles of human apoE: apoE2, apoE3, and apoE4. ApoE4 is a strong risk factor for Alzheimer's disease, whereas apoE2 is associated with lower risk for the disease [10]. This may reflect allele-specific differences in cholesterol delivery to neurons by LpE.

Other studies have examined the relationships between cholesterol levels and secretase activities. Depletion of cholesterol reduced  $\beta$ -secretase and  $\gamma$ -secretase activities, leading to decreased production of A $\beta$ , suggesting that  $\beta$ -secretase and  $\gamma$ -secretase function in lipid raft domains [11, 12]. Of note, A $\beta$  aggregation occurs in these domains [13].

ATP-binding cassette G1 (ABCG1) and ABCG4 are half-type ABC proteins that belong to the G subfamily of the ABC superfamily. ABCG1 and ABCG4 form functional homodimers [14], and may form heterodimers [15]. ABCG1 and ABCG4 mediate the efflux of cholesterol to HDL in human embryonic kidney (HEK) cells and baby hamster kidney cells [16–18]. ABCG1 and ABCG4 are highly expressed in the CNS and mediate the efflux of cholesterol to LpE [19–21]. ABCG1 is expressed in both neurons and astrocytes, whereas ABCG4 has been detected in neurons and astrocytes [22], as well as microglia from patients with Alzheimer's disease [23]. Both ABCG1 and ABCG4 are thought to be involved in sterol homeostasis in the body. A lack of *Abcg1* caused significant accumulation of neutral lipids in macrophages when the mutant mice were fed a high-fat, high-cholesterol diet [24]. Furthermore, mice lacking *Abcg1* showed severe age-dependent pulmonary lipidosis [25]. On the other hand, overexpression of ABCG1 protected murine tissues from lipid accumulation [24]. The absence of *Abcg4* in mice did not affect brain levels of cholesterol, whereas brain levels of lathosterol increased [26]. Moreover, ABCG4 mediated desmosterol efflux [26]. Double-knockout mice lacking *Abcg1* and *Abcg4* showed significantly increased desmosterol levels in the brain, suggesting that ABCG1 and ABCG4 have overlapping functions. Bojanic *et al.* reported that *Abcg4*<sup>-/-</sup> mice had a general deficit in associated fear memory, suggesting that ABCG4 contributes to neuronal plasticity via moving lipids [27]. Furthermore, *Abcg4*<sup>-/-</sup> mice showed increased proliferation of megakaryocyte progenitor cells, indicating that ABCG4 regulates proliferation of cells [28].

It has been reported that ABCA1, which is a member of the A subfamily and mediates the efflux of cholesterol and phosphatidylcholine to lipid-free apoA-I or apoE [14, 21, 29], reduced A $\beta$  secretion from cells [30, 31]. A $\beta$  deposition increased in the absence of *Abca1* in mouse models of Alzheimer's disease [32–34] and decreased by the overexpression of ABCA1 [35], although another study showed that the absence of *Abca1* did not affect A $\beta$  levels in mice [36]. Because, like ABCA1, ABCG1 removes excess cholesterol from cells and is expressed in the

CNS, we investigated the effects of the expression of ABCG1 on A $\beta$  secretion. Furthermore, ABCG1 has been reported to be associated with a risk for Alzheimer's disease [37]. Kim *et al.* demonstrated that expression of ABCG1 in Chinese hamster ovary cells that stably expressed APP suppressed A $\beta$  generation [21]. In contrast, Tansley *et al.* showed that ABCG1 expression in HEK cells expressing a Swedish-type APP mutant increased A $\beta$  secretion [38]. A $\beta$  levels in both ABCG1-overexpressing and *Abcg1*-deficient mice, however, were unchanged [39]. The reason for these discrepancies is unclear, as is the mechanism underlying altered APP processing in response to expression of ABCG1. Furthermore, no published studies have addressed on whether ABCG4 also affects APP processing.

We previously reported that ABCG1 mediates the efflux of sphingomyelin, phosphatidylcholine, and cholesterol from cells [14]. Furthermore, cholesterol and sphingomyelin synergistically stimulate ATP hydrolysis rate of purified ABCG1 [40]. Sphingomyelin and cholesterol form ordered microdomains (raft domains) in the plasma membrane. ABCG1 increases the cholesterol accessible to cholesterol oxidase [41], suggesting that ABCG1 decreases the raft domains and concomitantly increases the non-raft domains. We have demonstrated that the expression of ABCG1 and ABCG4 decreased the amounts of caveolin-1 in the raft domains [42], suggesting that ABCG1 and ABCG4 disturb the raft domains on the plasma membrane. Because  $\gamma$ -secretase functions in the raft domains [11, 43], we hypothesized that ABCG1 and ABCG4 affect  $\gamma$ -secretase activity and A $\beta$  secretion.

To assess the effects of ABCG4 on APP processing and to elucidate how ABCG1 alters APP processing, we examined APP processing and A $\beta$  secretion in cells expressing ABCG1 or ABCG4. We demonstrated that expression of ABCG1 or ABCG4 changed the distribution of  $\gamma$ -secretase on the plasma membrane and suppressed A $\beta$  secretion.

## Materials and Methods

### Materials

Mouse monoclonal anti-APP antibody was purchased from Covance (Princeton, NJ). Rat polyclonal anti-presenilin-1 antibody was obtained from Chemicon (Temecula, CA). Rabbit polyclonal anti-nicastrin antibody was obtained from Sigma-Aldrich (St. Louis, MO). Rabbit polyclonal anti-ABCG1 antibody was obtained from Santa Cruz (Dallas, Texas). HDL was acquired from Calbiochem (San Diego, CA). Other chemicals were purchased from Sigma-Aldrich, GE Healthcare (Little Chalfont, UK), Cayman Chemical (Ann Arbor, MI), Wako Pure Chemical Industries (Osaka, Japan), and Nacalai Tesque (Kyoto, Japan).

### Experimental animals

*Abcg1* null mouse with C57/BL6 background were purchased from Deltagen, Inc (San Mateo, CA). The C57BL/6 mice were obtained from a local supplier. The experiment animals were kept at the Center for Experimental Animal Science, Nagoya City University Graduate School of Medical Sciences Maintained with MF standard feeding chow (Oriental Yeast Co., Tokyo, Japan) in 25°C room with 12 h light–dark cycles. The experimental procedure was approved by Animal Welfare Committee of Nagoya City University Graduate School of Medical Sciences according to the institutional guidelines (approval number H13-112).

### Constructs

APP cDNA (GenBank accession number NM\_000484) was amplified from a human whole brain cDNA library by PCR using two primers (forward, 5'-aagcttgatgctgcccggttggc-3'; reverse, 5'-tctagactagttctgcatctgctcaag-3'). The cloned cDNA was subcloned into the *HindIII*-

*Xba*I sites of pCR2.1 (Invitrogen, Carlsbad, CA). A Swedish mutation (K594N and M595L) was introduced by changing g1782 and a1783 to c using a QuikChange II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) according to the manufacturer's instructions. Human Swedish mutant APP cDNA was inserted into the *Hind*III-*Xba*I sites of pcDNA3.1(+)*Hygro* (Invitrogen) to create the pcDNA3.1*Hygro*(+)/APPsw expression vector. Human ABCG4 cDNA [44] was inserted into the *Not*I and *Eco*RI sites of pcDNA3.1/*Hygro*(+) to create pcDNA3.1*Hygro*(+)/ABCG4. A Walker A lysine codon was changed to a methionine codon using a QuikChange II Site-Directed Mutagenesis Kit to create the pcDNA3.1*Hygro*(+)/ABCG4-KM expression vector.

## Cell culture

HEK293 cells and SH-SY5Y cells (American Type Culture Collection) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum in 5% CO<sub>2</sub> at 37°C.

## Establishment of a stable transformant of APPsw

HEK293 cells were transfected with pcDNA3.1*Hygro*(+)/APPsw using Lipofectamine (Invitrogen) according to the manufacturer's instructions. Cells were selected with hygromycin B for 5 days and single colonies were isolated.

## Transfection of ABCG1 and ABCG4

HEK293 or HEK293 cells stably expressing APPsw (HEK/APPsw) were transfected with pcDNA3.1(+)/ABCG1 [14], pcDNA3.1(+)/ABCG1-KM, pcDNA3.1*Hygro*(+)/ABCG4, or pcDNA3.1*Hygro*(+)ABCG4-KM using Lipofectamine according to the manufacturer's instructions.

## Reduction of ABCG1 or ABCG4 expression by RNA silencing

Control small interfering RNA (siRNA; Stealth RNAi Negative Control Medium GC Duplex #2); two siRNAs targeting human ABCG1, that is, ABCG1#1 (ABCG1-HSS145233) and ABCG1#2 (ABCG1-HSS-190466); and two siRNAs targeting human ABCG4, ABCG4#1 (ABCG4-HSS127417) and ABCG4#2 (ABCG4-HSS-127418) were purchased from Invitrogen. SH-SY5Y cells were transfected with 10 nM siRNAs using Lipofectamine RNAiMAX (Invitrogen) [45]. For differentiation of SH-SY5Y cells, 10  $\mu$ M all-*trans* retinoic acid was added to the culture medium and the cells were cultured for 3 days. After differentiation, SH-SY5Y cells were incubated for 16 h in DMEM containing 0.02% bovine serum albumin (BSA) in the presence or absence of 5  $\mu$ M TO901317, a synthetic ligand of liver X receptor (LXR) and 5  $\mu$ M 9-*cis* retinoic acid (RA), a ligand of retinoid X receptor (RXR).

## OptiPrep gradient ultracentrifugation

Cells were washed with phosphate-buffered saline and collected. The cells were resuspended in TNE buffer (25 mM Tris-Cl (pH 7.4), 5 mM EDTA, and 150 mM NaCl) containing 100  $\mu$ g/ml (*p*-aminophenyl)methanesulfonyl fluoride, 2  $\mu$ g/ml leupeptin, and 2  $\mu$ g/ml aprotinin, and passed through a 26-G needle 10 times. Broken cells were centrifuged at 3,000  $\times$  g for 5 min and TNE buffer containing 2% Triton X-100 was added to achieve a final Triton X-100 concentration of 1%. Samples were then incubated for 15 min on ice. Raft domains were isolated using a discontinuous OptiPrep gradient consisting of the following layers: 400  $\mu$ l of 35% opti and lysates, 1,600  $\mu$ l of 30% opti/TNE buffer, and 200  $\mu$ l of TNE buffer [46]. The gradient was

centrifuged in a TLS55 rotor (Beckman Coulter, Brea, CA) at 4°C for 4 h at 200,000  $\times$  g. After centrifugation, ten 200- $\mu$ l fractions were collected from the top of the tube and proteins were precipitated using acetone. The pellet was resuspended in SDS sample buffer and subjected to immunoblotting.

### Western blotting

Cells were washed with phosphate-buffered saline and lysed in lysis buffer (50 mM Tris-Cl (pH 7.5), 150 mM NaCl, and 1% Triton X-100) containing 100  $\mu$ g/ml (*p*-amidinophenyl) methanesulfonyl fluoride, 2  $\mu$ g/ml leupeptin, and 2  $\mu$ g/ml aprotinin. Samples were electrophoresed on a 5–20% or 10% SDS-polyacrylamide gel and detected with antibodies.

### Collection of mouse cerebrospinal fluid

Each mouse was exsanguinated under anesthetic maintenance to reduce vascular pressure. Cerebrospinal fluid (CSF) was harvest from cisterna magna, as described previously [47, 48]. In short, using a dissecting microscope, the cisterna magna carefully exposed. The arachnoid membrane was punctured with a 29G insulin syringe (TERUMO, Tokyo, Japan) and CSF was collected from the cistern compartment. The CSF was then transferred into microtubes and immediately frozen on dry ice, and stored at -80°C until the analysis.

### Measurement of A $\beta$ levels

Media were collected and A $\beta$ 40 and A $\beta$ 42 levels were measured using a Human  $\beta$  Amyloid ELISA Kit (Wako Pure Chemical Industries) according to the manufacturer's instructions. For mouse CSF A $\beta$  detection, Human/Rat  $\beta$  Amyloid (40) ELISA kit Wako II and (42) ELISA Kit Wako, High-Sensitive were used.

### Measurement of $\gamma$ -secretase activity

Cells were collected and  $\gamma$ -secretase activity was measured using a  $\gamma$ -secretase activity kit (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions.

### Statistical analysis

Values are presented as means  $\pm$  SD. Statistical significance among groups was determined using ANOVA followed by Dunnett's test.  $P < 0.05$  was considered statistically significant.

## Results

### ABCG1 and ABCG4 increase APP levels

The effects of ABCG4 have not been investigated, although the processing of APP in the presence of ABCG1 has been examined in the previous studies [21, 38]. To examine APP processing, ABCG1, ABCG4, and ABCG4-KM, which is a Walker A lysine mutant of ABCG4, were transiently expressed in HEK/APPsw cells. As reported by Kim *et al.* [21], cellular APP levels increased in response to expression of ABCG1 (Fig 1A and 1B). Two bands (130 and 100 kDa) were detected on immunoblots. The 130-kDa band was insensitive to endoglycosidase H but was sensitive to PNGase F, whereas the 100-kDa band was sensitive to both endoglycosidase H and PNGase F (data not shown), demonstrating that the bands were mature and immature forms of APP, respectively [49, 50]. Levels of mature and immature APP increased in cells expressing ABCG1 compared with mock-transfected cells. Expression of ABCG4 also increased the levels of mature APP, whereas expression of non-functional ABCG4-KM did






Fig. 1 Sano et al.

**Fig 1. ABCG1 and ABCG4 increased cellular and surface levels of APP.** (A) HEK/APPsw cells were transiently transfected with ABCG4, ABCG4-KM, or ABCG1, or mock-transfected. Twenty-four hours after transfection, cells were collected and cellular APP was detected by immunoblotting. Vinculin was used as a loading control. (B) The amounts of mature APP and immature APP detected by immunoblotting were analyzed. The data represent the expression levels of APP normalized by vinculin relative to that in mock-transfected cells. Values are represented with the SD. \*  $P < 0.05$ , significantly different from mock-transfected cells. (C) HEK/APPsw cells, transiently transfected with ABCG1 or ABCG4, or mock-transfected, were treated with sulfo-NHS-biotin followed by precipitation of biotinylated surface proteins using streptavidin agarose beads. Cell surface APP was detected by immunoblotting. All experiments were carried out in triplicate. (D) The amounts of cell surface APP detected by immunoblotting were analyzed. The data represent the expression levels of surface APP normalized by total APP proteins relative to that in mock-transfected cells. Values are represented with the SD. \*\*  $P < 0.01$ , significantly different from mock-transfected cells.

doi:10.1371/journal.pone.0155400.g001

not. Because APP is cleaved at the plasma membrane and/or in the endosome [12, 51, 52], cell surface APP levels were investigated in a biotinylation assay. ABCG1 and ABCG4 markedly increased amounts of APP in the plasma membrane (Fig 1C and 1D). To examine if this effect is specific to APP or universal to other proteins, we checked expression levels of another membrane protein, sodium potassium ATPase (S1A and S1B Fig). Neither ABCG1 nor ABCG4 affected expression of sodium potassium ATPase, suggesting that the increased expression is specific to APP. It is unlikely that transcription of APP was increased because cells stably expressing APP were used in this experiment. Thus, we speculated that the expression of ABCG1 and ABCG4 suppressed degradation of APP. Indeed, the half-life of APP increased in the presence of ABCG1 or ABCG4 (S2 Fig). When protein synthesis was inhibited in mock-transfected cells, less than 20% of the mature APP remained after 1 h. When ABCG1 or ABCG4 was expressed in the cells, about 40% of the mature APP remained after treatment with cycloheximide for 1 h. Next, we examined products of APP cleavage: sAPP $\alpha$ , sAPP $\beta$ , CTF $\alpha$ , and CTF $\beta$ . Levels of sAPP $\alpha$  and sAPP $\beta$  were higher in cells expressing ABCG1 or ABCG4 than in mock-transfected cells (Fig 2A and 2B). Levels of sAPP $\alpha$  and sAPP $\beta$  in cells expressing ABCG4-KM were similar with those in mock-transfected cells. Furthermore, expression of ABCG1 and ABCG4 in HEK/APPsw cells increased both CTF $\alpha$  and CTF $\beta$  (Fig 2C and 2D). These findings suggest that increased APP levels enhanced the production of sAPP $\alpha$ , sAPP $\beta$ , CTF $\alpha$ , and CTF $\beta$  by  $\alpha$ -secretase and  $\beta$ -secretase.

### Secreted A $\beta$ from cells expressing ABCG1 or ABCG4 is reduced

Accumulation of A $\beta$  is one of the characteristic features found in patients with Alzheimer's disease. To investigate whether A $\beta$  levels increased together with the elevation of CTF $\beta$  levels, we measured amounts of A $\beta$  secreted from cells expressing ABCG1 or ABCG4. We have shown that the presence of HDL in the medium enhances the efflux of lipids mediated by ABCG1


compared with that in the presence of only BSA [14]. Moreover, ABCG4 mediates efflux of cholesterol in an HDL-dependent manner [26]. To examine whether lipid efflux affected A $\beta$  secretion, the amounts of secreted A $\beta$  were measured in the presence or absence of HDL. Expression of ABCG1 in HEK/APPsw cells significantly suppressed the secretion of A $\beta$ 40 into the medium compared with levels observed for cells subjected to mock transfection (Fig 3A), which is consistent with the study by Kim *et al.* [21]. A $\beta$ 40 secretion was suppressed even in the absence of HDL in the medium, suggesting that lipid efflux is not necessary for the suppression of A $\beta$ 40 secretion. In the presence of HDL, more A $\beta$  was secreted from cells than in its absence. This suggests that HDL in the medium rather enhanced A $\beta$ 40 secretion. Expression of ABCG4 also suppressed the secretion of A $\beta$ 40, whereas expression of ABCG4-KM mutant did not affect it. Similar results were observed for A $\beta$ 42 (Fig 3B). ABCG1 and ABCG4 suppressed A $\beta$ 42 secretion irrespective of the presence of HDL, whereas ABCG4-KM did not affect the secretion of A $\beta$ 42. These findings indicate that, like ABCG1, ABCG4 decreased the production of A $\beta$ .

### ABCG1 and ABCG4 reduce $\gamma$ -secretase activity

Fig 3 suggests that the production of A $\beta$  by  $\gamma$ -secretase is reduced by ABCG1 and ABCG4, although the amounts of the  $\gamma$ -secretase substrate CTF $\beta$  increased (Fig 2). We speculated that  $\gamma$ -secretase activity was reduced by the expression of ABCG1 or ABCG4. To examine this, we measured  $\gamma$ -secretase activity. The activities of  $\gamma$ -secretase in cells expressing ABCG1 or ABCG4 were approximately 30% or 40% of that in mock-transfected cells, respectively (Fig 4), suggesting that the expression of either ABCG1 or ABCG4 reduces the  $\gamma$ -secretase activity.


### Distribution of $\gamma$ -secretase to raft domains is disturbed

We have shown that ABCG1 and ABCG4 disturb raft structure [42]. It has been reported that  $\gamma$ -secretase functions in raft domains [11, 43]. We speculated that disruption of raft structure




**Fig 2. ABCG1 and ABCG4 promoted the release of sAPP $\alpha$  and sAPP $\beta$ , and increased the levels of CTF $\alpha$  and CTF $\beta$ .** HEK/APPsw cells were transfected with ABCG4, ABCG4-KM, or ABCG1, or mock-transfected. Twenty-four hours after transfection, cells were incubated in DMEM containing 0.02% bovine serum albumin (BSA) for 24 h. (A) Media were collected, and sAPP $\alpha$  and sAPP $\beta$  levels were evaluated on immunoblots. (B) The amounts of sAPP $\alpha$  and sAPP $\beta$  detected by immunoblotting were analyzed. The data represent the expression levels of sAPP $\alpha$  and sAPP $\beta$  normalized by vinculin relative to that in mock-transfected cells. Values are represented with the SD. \*  $P < 0.05$ ; \*\*  $P < 0.01$  significantly different from mock-transfected cells. (C) Cells were collected, and cellular CTF $\alpha$  and CTF $\beta$  were detected by immunoblotting. (D) The amounts of CTF $\alpha$  and CTF $\beta$  detected by immunoblotting were analyzed. The data represent the expression levels of CTF normalized by vinculin relative to that in mock-transfected cells. Values are represented with the SD. \*\*  $P < 0.01$  significantly different from mock-transfected cells. All experiments were carried out in triplicate.

doi:10.1371/journal.pone.0155400.g002



**Fig 3. ABCG1 and ABCG4 suppressed A $\beta$  secretion.** HEK/APPsw cells were transiently transfected with ABCG4, ABCG4-KM, or ABCG1, or mock-transfected. Twenty-four hours after transfection, cells were incubated in DMEM containing 0.02% BSA (open bars) or 0.02% BSA and 20  $\mu$ g/ml HDL (filled bars) for 24 h. Media were collected, and A $\beta$ 40 (A) and A $\beta$ 42 (B) levels were measured using an enzyme-linked immunosorbent assay. Values from three experiments were normalized based on total cellular protein, and means are represented with the SD. \*  $P < 0.05$ ; \*\*  $P < 0.01$  compared with mock-transfected cells.


doi:10.1371/journal.pone.0155400.g003



**Fig 4. ABCG1 and ABCG4 suppressed  $\gamma$ -secretase activity.** HEK/APPsw cells were transfected with ABCG4 or ABCG1, or mock-transfected. Twenty-four hours after transfection, cells were incubated in DMEM containing 0.02% BSA for 24 h. The activity of endogenous  $\gamma$ -secretase was determined using a  $\gamma$ -secretase assay kit. Experiments were performed in triplicate and the activities relative to those observed in mock-transfected cells are represented as means with the SD. \*  $P < 0.05$ ; \*\*  $P < 0.01$  compared with mock-transfected cells.

doi:10.1371/journal.pone.0155400.g004





**Fig 5. Distribution of presenilin-1 was altered by ABCG1 or ABCG4.** (A) HEK293, HEK/ABCG4, HEK/ABCG4-KM, or HEK/ABCG1 cells were collected and presenilin-1 N-terminal fragment was detected by immunoblotting. (B) The amounts of presenilin-1 N-terminal fragment detected by immunoblotting were analyzed. The data represent the expression levels of presenilin-1 normalized by vinculin relative to that in HEK293 cells. Values are represented with the SD. (C) HEK293, HEK/ABCG4, HEK/ABCG4-KM, or HEK/ABCG1 cells were incubated in DMEM containing 0.02% BSA for 24 h, and treated with lysis buffer containing 1% Triton X-100 on ice. Cell lysates were separated using OptiPrep-gradient ultracentrifugation. Ten fractions from each sample were separated using 5–20% polyacrylamide gel electrophoresis, and presenilin-1 N-terminal fragment was detected by immunoblotting. (D) Presenilin-1 N-terminal fragment levels on Western blots were analyzed, and the average percentages of presenilin-1 in the raft domains (fractions 2 and 3) relative to total presenilin-1 levels (fractions 1–10) from five experiments are represented with the SD. \*\*  $P < 0.01$  compared with HEK293 cells.

doi:10.1371/journal.pone.0155400.g005

leads to decreased  $\gamma$ -secretase activity. To examine this, raft domains were separated using an OptiPrep gradient ultracentrifugation assay (S3 Fig). Caveolin-1, a raft marker, was distributed in raft fractions (fractions 2 and 3) in host HEK293 cells. Caveolin-1 was detected in raft fractions in HEK293 cells stably expressing ABCG4-KM (HEK/ABCG4-KM), but was hardly seen in HEK/ABCG1 and HEK/ABCG4 cells, as we reported previously [42]. Under this condition, the distribution of subunits of  $\gamma$ -secretase was investigated. The active  $\gamma$ -secretase is composed of 4 subunits: presenilin-1, nicastrin, PS-enhancer-2 (Pen-2), and anterior pharynx-defective-1 (APH-1). Among these, presenilin-1 is a catalytic subunit. Endogenous presenilin-1 was detected in HEK293 cells (Fig 5A). The expression levels of presenilin-1 were similar in HEK/ABCG4, HEK/ABCG4-KM, and HEK/ABCG1 cells (Fig 5A and 5B). Then, we examined if the distribution of presenilin-1 is affected by the expression of ABCG1 and ABCG4. In host HEK293 cells, endogenous presenilin-1 was distributed in raft fractions (fractions 2 and 3), whereas some was detected in non-raft fractions (fractions 8–10) (Fig 5C). Little presenilin-1 was observed in raft fractions from HEK/ABCG1 and HEK/ABCG4 cells, but it was detected in the non-raft fractions. In contrast, presenilin-1 was observed in raft fractions from HEK/ABCG4-KM cells. More than 30% of the presenilin-1 was localized in raft domains in HEK293 cells, but only 7% and 4% were detected in raft domains in HEK/ABCG1 and HEK/ABCG4

cells, respectively (Fig 5D). This result suggests that ABCG1 and ABCG4 reduce presenilin-1 levels in raft domains. There was no significant difference between the distributions of presenilin-1 in the raft domains of HEK293 and HEK/ABCG4-KM cells. This shows that the change in presenilin-1 localization was dependent on the ATPase activity of ABCG4. Similar results were observed for the other  $\gamma$ -secretase subunit nicastrin (S4 Fig). Endogenous nicastrin was detected in raft fractions from HEK293 and HEK/ABCG4-KM cells, whereas raft fractions from HEK/ABCG1 and HEK/ABCG4 cells did not contain nicastrin. These results suggest that ABCG1 and ABCG4 redistribute  $\gamma$ -secretase from raft domains to non-raft domains, possibly by destructing raft structures, and that the altered distribution reduces  $\gamma$ -secretase activity, leading to the reduced A $\beta$  secretion.

### Suppression of ABCG1 and ABCG4 increases $\gamma$ -secretase activity and A $\beta$ levels

Because the above experiments were performed using an overexpression system, we also examined the effects of endogenous ABCG1 and ABCG4 by using SH-SY5Y cells. SH-SY5Y cells were differentiated to neuron-like cells by all-*trans* retinoic acid, and ABCG1 and ABCG4 were suppressed by siRNAs. When differentiated SH-SY5Y cells were treated with TO901317 and 9-*cis* retinoic acid, i.e., ligands for LXR and RXR, respectively, ABCG1 expression was induced (S1C Fig). The expression level of ABCG1 in SH-SY5Y cells was lower than that in HEK293 cells transiently or stably expressing ABCG1, but the amount of endogenous ABCG1 in SH-SY5Y cells treated with TO901317 and 9-*cis* retinoic acid was comparable to that in ABCG1-overexpressing HEK293 cells (S1A, S1C and S1D Fig). Treatment of cells with two siRNAs against ABCG1 (ABCG1#1 and ABCG1#2) decreased the induced ABCG1 expression levels to less than half (Fig 6A and 6B). Without induction of ABCG1, siRNA treatment also reduced the ABCG1 level as compared to that for the control. Expression levels of ABCG1 in cells treated with two siRNAs against ABCG4 (ABCG4#1 and ABCG4#2) did not change. Because an antibody that recognizes endogenous ABCG4 is not available, we analyzed mRNA levels of ABCG4 (Fig 6C). Treatment of cells with TO901317 and 9-*cis* retinoic acid did not affect ABCG4 mRNA levels. The ABCG4 mRNA level significantly decreased when using the siRNA ABCG4#1, while ABCG4#2 relatively but not significantly reduced the ABCG4 mRNA level. siRNAs against ABCG1 did not change ABCG4 mRNA levels. Under this condition, endogenous APP levels were analyzed. Expression levels of APP, however, were low and it was difficult to quantify and compare them by western blotting (data not shown). Then, the amounts of A $\beta$  secreted from cells treated with TO901317 and 9-*cis* retinoic acid were measured in the absence of lipid acceptors (Fig 7). A $\beta$ 40 secretion increased when ABCG1 and ABCG4 were suppressed by ABCG1#1 and ABCG4#1, respectively, although it was not increased significantly by ABCG1#2 and ABCG4#2 treatment. A $\beta$ 42 secretion was increased by suppression of ABCG1 by ABCG1#1. We also measured  $\gamma$ -secretase activity to determine whether its alteration accounts for the altered A $\beta$  secretion. Suppression of ABCG1 and ABCG4 increased  $\gamma$ -secretase activity, except in the case of ABCG4#2 (Fig 8). These results support the idea that ABCG1 and ABCG4 affect  $\gamma$ -secretase activity, leading to altered A $\beta$  secretion.


### A $\beta$ mass in cerebrospinal fluid increased in *Abcg1* null mice

To examine the *in vivo* involvement of ABCG1 on modulating A $\beta$  level in CSF, CSF was harvested from twelve month or older (15.42 $\pm$ 3.95 month-old) C57BL/6 wild type and *Abcg1* null mice and A $\beta$  was measured (Fig 9). Statistically significantly higher levels of A $\beta$ 42 were observed in the *Abcg1* null mice (A $\beta$ 40; 0.750 $\pm$ 0.149 in WT vs 0.831 $\pm$ 0.062 fmole/ $\mu$ L in *Abcg1* null,  $P = 0.864$ ,  $n = 8$  and A $\beta$ 42; 0.177 $\pm$ 0.0291 in WT vs 0.220 $\pm$ 0.0149 fmole/ $\mu$ L in *Abcg1* null,

$P = 0.006$ ,  $n = 8$ ), which supports the concept that reduction of ABCG1 increases production of Aβ peptides in CSF.


### Discussion

In this study, we investigated the effects of ABCG1 and ABCG4 on APP processing and  $\gamma$ -secretase activity. We demonstrated that ABCG4 as well as ABCG1 suppressed Aβ production




**Fig 6. Suppression of ABCG1 and ABCG4 by siRNA.** (A) SH-SY5Y cells were transfected with siRNA against ABCG1, ABCG4, or scrambled siRNA (control), and allowed to differentiate for 3 days. After 16-h incubation with or without TO901317 (TO) and 9-*cis* retinoic acid (RA), cells were collected and ABCG1 was detected by immunoblotting. (B) The amount of ABCG1 detected by immunoblotting was analyzed. The data represent the expression levels of ABCG1 normalized by vinculin relative to those in control cells incubated with TO and RA. Values are represented with the SD. (C) Total RNA was extracted from differentiated SH-SY5Y cells. Quantitative RT-PCR was performed and the ABCG4 mRNA expression level was normalized to 18S rRNA. Relative expression levels of ABCG4 mRNA in cells transfected with siRNA are represented against those in control cells treated with TO and RA. \*  $P < 0.05$ ; \*\*  $P < 0.01$  compared with control cells incubated with TO and RA. All experiments were carried out in triplicate.

doi:10.1371/journal.pone.0155400.g006




**Fig 7. A $\beta$  secretion from SH-SY5Y cells.** SH-SY5Y cells were transfected with siRNA against ABCG1, ABCG4, or scrambled siRNA (control), and allowed to differentiate for 3 days. Cells were incubated in DMEM containing 0.02% BSA, 5  $\mu$ M TO901317 and 5  $\mu$ M 9-*cis* retinoic acid for 16 h. Media were collected and A $\beta$ 40 (A) and A $\beta$ 42 (B) levels were measured using an enzyme-linked immunosorbent assay. Values from three experiments were normalized based on total cellular protein, and means are represented with the SD. \*\*  $P < 0.01$  compared with control cells.

doi:10.1371/journal.pone.0155400.g007



**Fig 8.  $\gamma$ -secretase activity in SH-SY5Y cells.** SH-SY5Y cells were transfected with siRNA against ABCG1, ABCG4, or scrambled siRNA (control), and allowed to differentiate for 3 days. Cells were incubated in DMEM containing 0.02% BSA, 5  $\mu$ M TO901317, and 5  $\mu$ M 9-*cis* retinoic acid for 16 h. The activity of endogenous  $\gamma$ -secretase was determined using a  $\gamma$ -secretase assay kit. Experiments were performed in triplicate and the activities relative to those observed in control cells are represented as means with the SD. \*\*  $P < 0.01$  compared with control cells.

doi:10.1371/journal.pone.0155400.g008



**Fig 9. A $\beta$  in mouse CSF increased in Abcg1 null mice.** A $\beta$ 40 (A) and A $\beta$ 42 (B) levels of CSF were measured by ELISA Wako kit. Statistical significance was analyzed by Student's t-test. \*\*  $P < 0.01$  compared with wild type mice.

doi:10.1371/journal.pone.0155400.g009

and changed the localization of  $\gamma$ -secretase subunits from raft to non-raft domains. This is the first report that ABCG4 affects the processing of APP. Furthermore, we suggest that the altered distribution of  $\gamma$ -secretase causes the reduced secretion of A $\beta$ . We also demonstrated that A $\beta$  secretion from neuron-like cells in which ABCG1 and ABCG4 were suppressed increased and that A $\beta$ 42 in Abcg1 null mice significantly increased in CSF. These findings suggest that ABCG1 or ABCG4 can suppress A $\beta$  production and plaque formation of A $\beta$ .

There are conflicting reports about the effects of ABCG1 on the production of A $\beta$ . Kim *et al.* reported that transient expression of ABCG1 in Chinese hamster ovary cells that stably expressed human APP reduced A $\beta$  secretion without affecting cellular APP or soluble APP $\alpha$  levels [21]. On the other hand, Tansley *et al.* reported that transient expression of ABCG1 in HEK/APPsw cells increased the production of sAPP $\alpha$ , sAPP $\beta$ , CTF $\alpha$ , CTF $\beta$ , and A $\beta$ , possibly due to increased levels of APP on the plasma membrane [38]. In this study, we have shown that transient expression of ABCG1 in HEK/APPsw cells increased production of APP, sAPP $\alpha$ , sAPP $\beta$ , CTF $\alpha$ , and CTF $\beta$  but decreased the secretion of A $\beta$ . We used a similar expression system as Tansley *et al.*, and our results are consistent with their study in terms of the increased production of APP, sAPP $\alpha$ , sAPP $\beta$ , CTF $\alpha$ , and CTF $\beta$ . Our result is, however, consistent with Kim's study but not with Tansley's study with regard to the secreted A $\beta$  levels. The reason for this discrepancy is unclear, although differences in ABCG1 expression levels between the studies may be one of the causes of different A $\beta$  levels. Alternatively, the culture conditions may have affected A $\beta$  levels, because an absence of HDL suppressed A $\beta$  levels as shown in Fig 3, suggesting that the effects of ABCG1 and ABCG4 are dependent on the presence of cholesterol acceptors and donors. The different cell lines may have resulted in different levels of APP, sAPP $\alpha$ , sAPP $\beta$ , CTF $\alpha$ , and CTF $\beta$ . If this is the case, studies using neurons are essential to understand the effects of ABCG1 on APP processing and A $\beta$  secretion in the CNS and to reveal the relationship between the expression of ABCG1 and Alzheimer's disease.

M $\beta$ CD extracted cholesterol from cells and decreased A $\beta$  secretion (data not shown) [5, 11, 12]. The mechanism underlying this process, however, likely differs from that involving ABCG1 and ABCG4. Expression of ABCG1 or ABCG4 increased the levels of cellular APP, sAPP $\alpha$ , and sAPP $\beta$ , whereas M $\beta$ CD treatment did not change cellular APP levels, increased sAPP $\alpha$  levels, and decreased sAPP $\beta$  levels (data not shown). We suggest that the effects of M $\beta$ CD were a consequence of removing cholesterol from the plasma membrane, and that the

effects of ABCG1 and ABCG4 were caused by cholesterol redistribution in the plasma membrane because A $\beta$  secretion was suppressed even under the condition without lipid acceptors, in which ABCG1- or ABCG4-mediated lipid efflux did not occur. Kim *et al.* also showed that A $\beta$  generation was suppressed by ABCG1 even in the absence of lipid acceptors, such as apoE-disc [21]. These results suggest that suppressed A $\beta$  secretion is not dependent on the lipid efflux by ABCG1 or ABCG4. Suppressed A $\beta$  secretion was not observed in the cells expressing ABCG4-KM, suggesting that the ATPase activity of ABCG4 was required for the suppression. Therefore, ABCG1- and ABCG4-mediated lipid redistribution may lead to decreased secretion of A $\beta$ .

Previous reports showed that ABCA1 expression suppressed the secretion of A $\beta$  even in the absence of apoA-I [30, 31]; one report, however, demonstrated that ABCA1 increased A $\beta$  secretion [36]. In the current study, we showed that both ABCG1 and ABCG4 reduced A $\beta$  secretion, which was independent of lipid efflux. Thus, ABCA1, ABCG1, and ABCG4 may suppress A $\beta$  secretion via a common mechanism. We demonstrated that the distributions of  $\gamma$ -secretase subunits on the plasma membrane changed and  $\gamma$ -secretase activity was reduced in the presence of ABCG1 or ABCG4. It has been reported that ABCA1 and ABCG1 redistributed membrane lipids and increased the amount of cholesterol accessible to cholesterol oxidase [41, 53], suggesting that ABCA1 and ABCG1 disrupt the raft domains, and consequently increased the area of non-raft domains. ABCG1 has been reported to reduce the sizes of lipid rafts [54]. Furthermore, we have demonstrated that ABCG1 and ABCG4 disturb raft domains [42]. Disruption of raft domains by ABCG1 and ABCG4 may disturb the localization of  $\gamma$ -secretase in the raft domains and reduce  $\gamma$ -secretase activity. This model is supported by data showing that M $\beta$ CD treatment, which reduces the areas of raft domains, also decreased  $\gamma$ -secretase levels in the raft domains and  $\gamma$ -secretase activity [11, 43]. Therefore, ABCA1, ABCG1, and ABCG4 may modulate raft domain structures, leading to reduced  $\gamma$ -secretase activity and A $\beta$  secretion. A $\beta$  secretion was suppressed both in the presence or absence of HDL. Surprisingly, HDL slightly suppressed effects of ABCG1 and ABCG4 on A $\beta$  secretion rather than enhance them. HDL may suppress disruption of raft domains by exchange of cholesterol between HDL and membranes. These suggest that lipid redistribution but not lipid efflux is responsible for modulation of raft domains and reduced A $\beta$  secretion. Furthermore, ABCA1, ABCG1, and ABCG4 may suppress A $\beta$  aggregation because aggregation of A $\beta$  occurs in the raft domains [13].

Because less A $\beta$  was secreted irrespective of increased levels of the  $\gamma$ -secretase substrate CTF $\beta$ , it is likely that reduced  $\gamma$ -secretase activity is responsible for the decreased A $\beta$  secretion. We, however, cannot exclude the possibility that ABCG1 and ABCG4 affect the activities of  $\alpha$ -secretase and  $\beta$ -secretase in addition to  $\gamma$ -secretase. Because  $\beta$ -secretase has been reported to reside in the raft domains [55],  $\beta$ -secretase activity may be also modulated by ABCG1 and ABCG4. Further studies to clarify the effects of ABCG1 and ABCG4 on overall APP processing are needed.

Cellular APP levels and especially surface APP levels were increased by the expression of ABCG1 and ABCG4. This is not because transcription of APP was induced, because mRNA level of APP was not altered by ABCG1 or ABCG4 (S5 Fig). APP may accumulate in cells because  $\gamma$ -secretase activity was reduced by ABCG1 and ABCG4. The rate of cellular APP degradation was slightly reduced by ABCG1 or ABCG4 (S2 Fig). Furthermore, endocytosis of APP may be suppressed because inhibition of endocytosis increased the amounts of cell surface APP [51]. Suppressed endocytosis may be one factor that reduces A $\beta$  production because endocytosis is essential for  $\beta$ -cleavage [12]. Expression of ABCG1 and ABCG4 may alter membrane trafficking via lipid redistribution. Presenilin-1 levels were not affected by expression of ABCG1 and ABCG4, while APP levels increased in cells expressing ABCG1 and ABCG4. Disturbed raft domains by ABCG1 and ABCG4 may affect APP and presenilin-1 levels differently, because



APP and presenilin-1 localize to distinct membrane domains [56]. Alternatively, APP degradation is suppressed but presenilin-1 degradation may not be affected by expression of ABCG1 and ABCG4.

A $\beta$ 40 secretion increased when endogenous ABCG1 and ABCG4 were suppressed in differentiated SH-SY5Y cells. A $\beta$ 42 secretion was also increased by suppression of ABCG1 but the increase was not significant in the case of suppression of ABCG4. ABCA1 expression might be elevated to compensate for the reduced expression of ABCG1 and ABCG4, which weakened the effects of knockdown. A $\beta$  secretion from SH-SY5Y cells and  $\gamma$ -secretase activity increased when ABCG1 and ABCG4 were suppressed, suggesting that ABCG1 and ABCG4 reduce  $\gamma$ -secretase activity and A $\beta$  secretion and are physiologically relevant for regulation of A $\beta$  levels.

A $\beta$ 42 in Abcg1 null mice was significantly increased in CSF in this study. The level of this peptide in CSF has been shown to be a relatively good marker for progression of Alzheimer's disease. The experimental animals used in this study were older than one-year ( $15.4 \pm 3.95$  month), which is approximately half of their life span. The previous report [39], using relatively younger mice, evaluated A $\beta$  from hippocampi tissue which presumably include CSF, interstitial fluid [57], and cytosol of neuronal and glial cells. A $\beta$  level in CSF from this mouse model system was not indicated. The brain system is highly evolved in human compared to other organs such as liver cells or muscle cells. Thus, there are limitation using model mice to anticipate human neuronal diseases while at least one of the inter brain fluid system, CSF, indicated significantly increased A $\beta$  level by the raft condition modified by ABCG1. Alzheimer's disease is also known to occur at a higher incidence in females [58], so in the future, it will be important to investigate the presence of any gender differences in the accumulation of A $\beta$ 42 in Abcg1 null mice.

In summary, we have shown that the ABCG1 and ABCG4 but not ABCG4-KM affected APP processing. We demonstrated that expression of ABCG1 and ABCG4 relocated  $\gamma$ -secretase and reduced its activity, which led to the reduced A $\beta$  secretion. Furthermore, we showed that A $\beta$  secretion from neuron-like cells increased when ABCG1 and ABCG4 were suppressed and that A $\beta$ 42 level in CSF significantly increased in Abcg1 null mice compared to the wild type mice. ABCG1 and ABCG4 may play important roles in suppression of A $\beta$  generation and pathogenesis of Alzheimer's disease. ABCG1 and ABCG4 could be new targets for prevention and treatment of Alzheimer's disease. Inducing expression or activity of ABCG1 and ABCG4 in the CNS may prevent amyloid plaque formation by reducing A $\beta$  production.

## Supporting Information

**S1 Fig. Expression of ABCG1, ABCG4, and sodium potassium ATPase in HEK293 and SH-SY5Y cells.** (A) HEK/APPsw cells were transiently transfected with ABCG4, ABCG4-KM, or ABCG1, or mock-transfected. Twenty-four hours after transfection, cells were collected and ABCG1, ABCG4, and sodium potassium ATPase (Na, K-ATPase) alpha1 subunit were detected by immunoblotting. (B) The amounts of Na, K-ATPase alpha1 subunit detected by immunoblotting were analyzed. The data represent the expression levels of Na, K-ATPase alpha1 subunit normalized by vinculin relative to that in mock-transfected cells. Values are represented with the SD. (C) SH-SY5Y cells were allowed to differentiate for 3 days. After 16-h incubation with or without TO901317 (TO) and 9-*cis* retinoic acid (RA), cells were collected and ABCG1, ABCG4, and Na, K-ATPase alpha1 subunit were detected by immunoblotting. (D) HEK293, HEK/ABCG4, HEK/ABCG4-KM, or HEK/ABCG1 cells were collected and ABCG1, ABCG4, and Na, K-ATPase alpha1 subunit were detected by immunoblotting. (TIF)

**S2 Fig. Half-life of APP was extended by ABCG1 or ABCG4.** (A) HEK/APPsw cells were transiently transfected with ABCG1 or ABCG4, or mock-transfected. Twenty-four hours after

transfection, 100  $\mu$ g/ml cycloheximide was added to the medium; cells were collected after 0, 0.5, 1, 2, and 4 h; and cellular APP was detected by immunoblotting. (B) Mature and immature APP levels on Western blots were analyzed, and the average percentages of remaining APP relative to APP levels just before adding cycloheximide are represented with the SD. (TIF)

**S3 Fig. Distribution of caveolin-1 was altered by ABCG1 or ABCG4.** (A) HEK293, HEK/ABCG4, HEK/ABCG4-KM, or HEK/ABCG1 cells were incubated in DMEM containing 0.02% BSA for 24 h, and treated with lysis buffer containing 1% Triton X-100 on ice. Cell lysates were separated using OptiPrep-gradient ultracentrifugation. Ten fractions from each sample were separated using 5–20% polyacrylamide gel electrophoresis, and caveolin-1 was detected by immunoblotting. (TIF)

**S4 Fig. Distribution of nicastrin was altered by ABCG1 or ABCG4.** HEK293, HEK/ABCG4, HEK/ABCG4-KM, or HEK/ABCG1 cells were incubated in DMEM containing 0.02% BSA for 24 h, and treated with lysis buffer containing 1% Triton X-100 on ice. Cell lysates were separated using OptiPrep-gradient ultracentrifugation. Ten fractions from each sample were separated using 5–20% polyacrylamide gel electrophoresis, and nicastrin was detected by immunoblotting. (TIF)

**S5 Fig. APP mRNA level was not changed by ABCG1 or ABCG4.** Total RNA was extracted from HEK293, HEK/ABCG4, HEK/ABCG4-KM, or HEK/ABCG1 cells. Quantitative RT-PCR was performed and APP mRNA expression level was normalized to 18S rRNA. Relative expression levels of APP mRNA in HEK/ABCG4, HEK/ABCG4-KM, or HEK/ABCG1 cells were represented against that in host HEK293 cells. (TIF)

## Author Contributions

Conceived and designed the experiments: OS MT YS KU M. Matsuo. Performed the experiments: OS MT YS RK M. Matsuo. Analyzed the data: OS MT M. Matsuo. Contributed reagents/materials/analysis tools: AK ATR. Wrote the paper: MT NK M. Michikawa KU M. Matsuo.

## References

1. Mattson MP. Pathways towards and away from Alzheimer's disease. *Nature*. 2004; 430(7000):631–9. PMID: [15295589](#)
2. Vance JE, Hayashi H. Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. *Biochimica et Biophysica Acta*. 2010; 1801(8):806–18. doi: [10.1016/j.bbaliip.2010.02.007](#) PMID: [20170744](#)
3. Pfrieger FW, Barres BA. Synaptic Efficacy Enhanced by Glial Cells in Vitro. *Science*. 1997; 277(5332):1684–7. PMID: [9287225](#)
4. Matsuo M, Campenot RB, Vance DE, Ueda K, Vance JE. Involvement of low-density lipoprotein receptor-related protein and ABCG1 in stimulation of axonal extension by apoE-containing lipoproteins. *Biochim Biophys Acta*. 2011; 1811(1):31–8. doi: [10.1016/j.bbaliip.2010.10.004](#) PMID: [21040802](#)
5. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. *Proc Natl Acad Sci USA*. 1998; 95(11):6460–4. PMID: [9600988](#)
6. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease  $\beta$ -amyloid peptides A $\beta$ 42 and A $\beta$ 40 in vitro and in vivo. *Proc Natl Acad Sci USA*. 2001; 98(10):5856–61. PMID: [11296263](#)

7. Refolo LM, Pappolla MA, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, et al. Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model. *Neurobiol Dis.* 2000; 7(4):321–31. PMID: [10964604](#)
8. Shie F-S, Jin L-W, Cook DG, Leverenz JB, LeBoeuf RCCA. Diet-induced hypercholesterolemia enhances brain A[ $\beta$ ] accumulation in transgenic mice. *Neuroreport.* 2002; 13(4):455–9. PMID: [11930160](#)
9. Mori TDVMP Paris DP, Town TB Rojjiani AMMDP, Sparks DLP, Delledonne A, et al. Cholesterol Accumulates in Senile Plaques of Alzheimer Disease Patients and in Transgenic APPsw Mice. *J Neuro-pathol Exp Neurol.* 2001; 60(8):778–85. PMID: [11487052](#)
10. Kim J, Basak JM, Holtzman DM. The Role of Apolipoprotein E in Alzheimer's Disease. *Neuron.* 2009; 63(3):287–303. doi: [10.1016/j.neuron.2009.06.026](#) PMID: [19679070](#)
11. Wahrle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, et al. Cholesterol-Dependent [gamma]-Secretase Activity in Buoyant Cholesterol-Rich Membrane Microdomains. *Neurobiol Dis.* 2002; 9(1):11–23. PMID: [11848681](#)
12. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer {beta}-amyloid precursor protein depends on lipid rafts. *J Cell Biol.* 2003; 160(1):113–23. PMID: [12515826](#)
13. Wakabayashi M, Okada T, Kozutsumi Y, Matsuzaki K. GM1 ganglioside-mediated accumulation of amyloid [beta]-protein on cell membranes. *Biochem Biophys Res Commun.* 2005; 328(4):1019–23. PMID: [15707979](#)
14. Kobayashi A, Takanezawa Y, Hirata T, Shimizu Y, Misasa K, Kioka N, et al. Efflux of sphingomyelin, cholesterol, and phosphatidylcholine by ABCG1. *J Lipid Res.* 2006; 47(8):1791–802. PMID: [16702602](#)
15. Cserepes J, Szentpetery Z, Seres L, Ozvegy-Laczka C, Langmann T, Schmitz G, et al. Functional expression and characterization of the human ABCG1 and ABCG4 proteins: indications for heterodimerization. *Biochem Biophys Res Commun.* 2004; 320(3):860–7. PMID: [15240127](#)
16. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. *Proc Natl Acad Sci USA.* 2004; 101(26):9774–9. PMID: [15210959](#)
17. Vaughan AM, Oram JF. ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL. *J Lipid Res.* 2006; 47(11):2433–43. PMID: [16902247](#)
18. Gelissen IC, Harris M, Rye KA, Quinn C, Brown AJ, Kockx M, et al. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. *Arterioscler Thromb Vasc Biol.* 2006; 26(3):534–40. PMID: [16357317](#)
19. Abildayeva K, Jansen PJ, Hirsch-Reinshagen V, Bloks VW, Bakker AHF, Ramaekers FCS, et al. 24 (S)-Hydroxycholesterol Participates in a Liver X Receptor-controlled Pathway in Astrocytes That Regulates Apolipoprotein E-mediated Cholesterol Efflux. *J Biol Chem.* 2006; 281(18):12799–808. doi: [10.1074/jbc.M601019200](#) PMID: [16524875](#)
20. Karten B, Campenot RB, Vance DE, Vance JE. Expression of ABCG1, but Not ABCA1, Correlates with Cholesterol Release by Cerebellar Astroglia. *J Biol Chem.* 2006; 281(7):4049–57. doi: [10.1074/jbc.M508915200](#) PMID: [16352604](#)
21. Kim WS, Rahmanto AS, Kamili A, Rye K-A, Guillemin GJ, Gelissen IC, et al. Role of ABCG1 and ABCA1 in Regulation of Neuronal Cholesterol Efflux to Apolipoprotein E Discs and Suppression of Amyloid-beta Peptide Generation. *J Biol Chem.* 2007; 282(5):2851–61. doi: [10.1074/jbc.M607831200](#) PMID: [17121837](#)
22. Tarr PT, Edwards PA. ABCG1 and ABCG4 are coexpressed in neurons and astrocytes of the CNS and regulate cholesterol homeostasis through SREBP-2. *J Lipid Res.* 2008; 49(1):169–82. PMID: [17916878](#)
23. Uehara Y, Yamada T, Baba Y, Miura S-i, Abe S, Kitajima K, et al. ATP-binding cassette transporter G4 is highly expressed in microglia in Alzheimer's brain. *Brain Res.* 2008; 1217:239–46. doi: [10.1016/j.brainres.2008.04.048](#) PMID: [18508037](#)
24. Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, Fishbein MC, et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. *Cell Metab.* 2005; 1(2):121–31. PMID: [16054053](#)
25. Baldan A, Tarr P, Vales CS, Frank J, Shimotake TK, Hawgood S, et al. Deletion of the Transmembrane Transporter ABCG1 Results in Progressive Pulmonary Lipidosis. *J Biol Chem.* 2006; 281(39):29401–10. PMID: [16887795](#)
26. Wang N, Yvan-Charvet L, Lutjohann D, Mulder M, Vanmierlo T, Kim T-W, et al. ATP-binding cassette transporters G1 and G4 mediate cholesterol and desmosterol efflux to HDL and regulate sterol accumulation in the brain. *FASEB J.* 2008; 22(4):1073–82. PMID: [18039927](#)

27. Bojanic DD, Tarr PT, Gale GD, Smith DJ, Bok D, Chen B, et al. Differential expression and function of ABCG1 and ABCG4 during development and aging. *J Lipid Res.* 2010; 51(1):169–81. doi: [10.1194/M900250-JLR200](https://doi.org/10.1194/M900250-JLR200) PMID: [19633360](https://pubmed.ncbi.nlm.nih.gov/19633360/)
28. Murphy AJ, Bijl N, Yvan-Charvet L, Welch CB, Bhagwat N, Reheman A, et al. Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. *Nat Med.* 2013; 19(5):586–94. doi: [10.1038/nm.3150](https://doi.org/10.1038/nm.3150) PMID: [23584088](https://pubmed.ncbi.nlm.nih.gov/23584088/)
29. Tanaka AR, Abe-Dohmae S, Ohnishi T, Aoki R, Morinaga G, Okuhira K-i, et al. Effects of Mutations of ABCA1 in the First Extracellular Domain on Subcellular Trafficking and ATP Binding/Hydrolysis. *J Biol Chem.* 2003; 278(10):8815–9. PMID: [12509412](https://pubmed.ncbi.nlm.nih.gov/12509412/)
30. Koldamova RP, Lefterov IM, Ikonovic MD, Skoko J, Lefterov PI, Isanski BA, et al. 22R-Hydroxycholesterol and 9-cis-Retinoic Acid Induce ATP-binding Cassette Transporter A1 Expression and Cholesterol Efflux in Brain Cells and Decrease Amyloid beta Secretion. *J Biol Chem.* 2003; 278(15):13244–56. PMID: [12547833](https://pubmed.ncbi.nlm.nih.gov/12547833/)
31. Sun Y, Yao J, Kim T-W, Tall AR. Expression of Liver X Receptor Target Genes Decreases Cellular Amyloid (beta) Peptide Secretion. *J Biol Chem.* 2003; 278(30):27688–94. PMID: [12754201](https://pubmed.ncbi.nlm.nih.gov/12754201/)
32. Koldamova R, Staufienbiel M, Lefterov I. Lack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice. *J Biol Chem.* 2005; 280(52):43224–35. doi: [10.1074/jbc.M504513200](https://doi.org/10.1074/jbc.M504513200) PMID: [16207713](https://pubmed.ncbi.nlm.nih.gov/16207713/)
33. Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain J-F, Naus KE, Mclsaac SA, et al. The Absence of ABCA1 Decreases Soluble ApoE Levels but Does Not Diminish Amyloid Deposition in Two Murine Models of Alzheimer Disease. *J Biol Chem.* 2005; 280(52):43243–56. doi: [10.1074/jbc.M508781200](https://doi.org/10.1074/jbc.M508781200) PMID: [16207707](https://pubmed.ncbi.nlm.nih.gov/16207707/)
34. Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, et al. Deletion of Abca1 Increases A $\beta$  Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease. *J Biol Chem.* 2005; 280(52):43236–42. doi: [10.1074/jbc.M508780200](https://doi.org/10.1074/jbc.M508780200) PMID: [16207708](https://pubmed.ncbi.nlm.nih.gov/16207708/)
35. Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. *J Clin Invest.* 2008; 118(2):671–82. doi: [10.1172/JCI33622](https://doi.org/10.1172/JCI33622) PMID: [18202749](https://pubmed.ncbi.nlm.nih.gov/18202749/)
36. Fukumoto H, Deng A, Irizarry MC, Fitzgerald ML, Rebeck GW. Induction of the Cholesterol Transporter ABCA1 in Central Nervous System Cells by Liver X Receptor Agonists Increases Secreted A $\beta$  Levels. *J Biol Chem.* 2002; 277(50):48508–13. PMID: [12384498](https://pubmed.ncbi.nlm.nih.gov/12384498/)
37. Wollmer M, Slegers K, Ingelsson M, Zekanowski C, Brouwers N, Maruszak A, et al. Association study of cholesterol-related genes in Alzheimer's disease. *Neurogenetics.* 2007; 8(3):179–88. PMID: [17387528](https://pubmed.ncbi.nlm.nih.gov/17387528/)
38. Tansley GH, Burgess BL, Bryan MT, Su Y, Hirsch-Reinshagen V, Pearce J, et al. The cholesterol transporter ABCG1 modulates the subcellular distribution and proteolytic processing of (beta)-amyloid precursor protein. *J Lipid Res.* 2007; 48(5):1022–34. doi: [10.1194/jlr.M600542-JLR200](https://doi.org/10.1194/jlr.M600542-JLR200) PMID: [17293612](https://pubmed.ncbi.nlm.nih.gov/17293612/)
39. Burgess BL, Parkinson PF, Racke MM, Hirsch-Reinshagen V, Fan J, Wong C, et al. ABCG1 influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo. *J Lipid Res.* 2008; 49(6):1254–67. doi: [10.1194/jlr.M700481-JLR200](https://doi.org/10.1194/jlr.M700481-JLR200) PMID: [18314463](https://pubmed.ncbi.nlm.nih.gov/18314463/)
40. Hirayama H, Kimura Y, Kioka N, Matsuo M, Ueda K. ATPase activity of human ABCG1 is stimulated by cholesterol and sphingomyelin. *J Lipid Res.* 2013; 54(2):496–502. doi: [10.1194/jlr.M033209](https://doi.org/10.1194/jlr.M033209) PMID: [23172659](https://pubmed.ncbi.nlm.nih.gov/23172659/)
41. Vaughan AM, Oram JF. ABCG1 Redistributes Cell Cholesterol to Domains Removable by High Density Lipoprotein but Not by Lipid-depleted Apolipoproteins. *J Biol Chem.* 2005; 280(34):30150–7. PMID: [15994327](https://pubmed.ncbi.nlm.nih.gov/15994327/)
42. Sano O, Ito S, Kato R, Shimizu Y, Kobayashi A, Kimura Y, et al. ABCA1, ABCG1, and ABCG4 Are Distributed to Distinct Membrane Meso-Domains and Disturb Detergent-Resistant Domains on the Plasma Membrane. *PLoS ONE.* 2014; 9(10):e109886. doi: [10.1371/journal.pone.0109886](https://doi.org/10.1371/journal.pone.0109886) PMID: [25302608](https://pubmed.ncbi.nlm.nih.gov/25302608/)
43. Urano Y, Hayashi I, Isoo N, Reid PC, Shibasaki Y, Noguchi N, et al. Association of active (gamma)-secretase complex with lipid rafts. *J Lipid Res.* 2005; 46(5):904–12. doi: [10.1194/jlr.M400333-JLR200](https://doi.org/10.1194/jlr.M400333-JLR200) PMID: [15716592](https://pubmed.ncbi.nlm.nih.gov/15716592/)
44. Hirata T, Okabe M, Kobayashi A, Ueda K, Matsuo M. Molecular mechanisms of subcellular localization of ABCG5 and ABCG8. *Biosci Biotechnol Biochem.* 2009; 73(3):619–26. PMID: [19270375](https://pubmed.ncbi.nlm.nih.gov/19270375/)
45. Matsuda A, Nagao K, Matsuo M, Kioka N, Ueda K. 24(S)-hydroxycholesterol is actively eliminated from neuronal cells by ABCA1. *J Neurochem.* 2013; 126(1):93–101. doi: [10.1111/jnc.12275](https://doi.org/10.1111/jnc.12275) PMID: [23600914](https://pubmed.ncbi.nlm.nih.gov/23600914/)

46. Jacobs C, Onnockx S, Vandenbroere I, Pirson I. Endogenous SHIP2 does not localize in lipid rafts in 3T3-L1 adipocytes. *FEBS Lett.* 2004; 565(1–3):70–4. PMID: [15135055](#)
47. DeMattos RB, Bales KR, Parsadanian M, O'Dell MA, Foss EM, Paul SM, et al. Plaque-associated disruption of CSF and plasma amyloid-beta (A $\beta$ ) equilibrium in a mouse model of Alzheimer's disease. *J Neurochem.* 2002; 81(2):229–36. PMID: [12064470](#)
48. Liu L, Duff K. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. *J Vis Exp.* 2008;(21):960. doi: [10.3791/960](#) PMID: [19066529](#)
49. Pahlsson P, Spitalnik SL. The Role of Glycosylation in Synthesis and Secretion of [beta]-Amyloid Precursor Protein by Chinese Hamster Ovary Cells. *Arch Biochem Biophys.* 1996; 331(2):177–86. PMID: [8660696](#)
50. Tomita S, Kirino Y, Suzuki T. Cleavage of Alzheimer's Amyloid Precursor Protein (APP) by Secretases Occurs after O-Glycosylation of APP in the Protein Secretory Pathway. *J Biol Chem.* 1998; 273(11):6277–84. PMID: [9497354](#)
51. Chyung JH, Selkoe DJ. Inhibition of Receptor-mediated Endocytosis Demonstrates Generation of Amyloid beta-Protein at the Cell Surface. *J Biol Chem.* 2003; 278(51):51035–43. doi: [10.1074/jbc.M304989200](#) PMID: [14525989](#)
52. Kinoshita A, Fukumoto H, Shah T, Whelan CM, Irizarry MC, Hyman BT. Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. *J Cell Sci.* 2003; 116(16):3339–46. doi: [10.1242/jcs.00643](#)
53. Vaughan AM, Oram JF. ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions. *J Lipid Res.* 2003; 44(7):1373–80. PMID: [12700343](#)
54. Pommier AJC, Alves G, Viennois E, Bernard S, Communal Y, Sion B, et al. Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells. *Oncogene.* 2010; 29(18):2712–23. doi: [10.1038/onc.2010.30](#) PMID: [20190811](#)
55. Hattori C, Asai M, Onishi H, Sasagawa N, Hashimoto Y, Saido TC, et al. BACE1 interacts with lipid raft proteins. *J Neurosci Res.* 2006; 84(4):912–7. PMID: [16823808](#)
56. Vetrivel KS, Cheng H, Kim S-H, Chen Y, Barnes NY, Parent AT, et al. Spatial Segregation of  $\gamma$ -Secretase and Substrates in Distinct Membrane Domains. *J Biol Chem.* 2005; 280(27):25892–900. doi: [10.1074/jbc.M503570200](#) PMID: [15886206](#)
57. Carare RO, Hawkes CA, Weller RO. Afferent and efferent immunological pathways of the brain. *Anatomy, Function and Failure.* *Brain Behav Immun.* 2014; 36(0):9–14.
58. Holland D, Desikan RS, Dale AM, McEvoy LK. Higher rates of decline for women and apolipoprotein E epsilon4 carriers. *Am J Neuroradiol.* 2013; 34(12):2287–93. doi: [10.3174/ajnr.A3601](#) PMID: [23828104](#)